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Background. An increasing popularity of ultra-endurance events coupled with excessive or inappropriate non-steroidal anti-inflammatory 
drug (NSAID) use during such events could pose considerable potential risks to runners’ health.
Objective. To evaluate the incidence of NSAID and other analgesic use in distance runners during training, competition and recovery.
Methods. We performed an observational cross-sectional study at the Desert Race Across the Sand race (Colorado to Utah, USA) in June 
2011 and the Empire State Marathon half-marathon, and relay races in Syracuse, NY, October 2011. A total of 27 ultramarathon runners 
and 46 marathon, half-marathon and marathon relay runners participated in the study. Surveys were distributed to runners during race 
registration. Self-reported use of common analgesic medications during training, racing and recovery was assessed.
Results. Among all runners at all stages, NSAIDs were the most commonly used analgesic medication. NSAID use by ultramarathon 
runners compared with all other runners was similar during training (59% and 63%, respectively; χ2=0.008; p=0.93) and recovery (59% 
and 61%, respectively; χ2=0.007; p=0.93). However, ultramarathon runners were more likely than all other runners to use NSAIDs during 
the race (70% and 26%, respectively; χ2=11.76; p=0.0006). 
Conclusion. Despite undesirable side-effects associated with the use of NSAIDs, there was a high prevalence of use in all runners, particularly 
during training and recovery. NSAID use during the race was significantly greater in ultramarathon runners. Medical staff at endurance 
events need to be aware of, and prepared for potential complications related to the high use of NSAIDs in runners. Future efforts should 
focus on teaching runners about the undesirable effects of medication and emphasising alternatives to pain medication.
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Ultra-endurance sports are increasing rapidly in 
popularity, with recent exponential growth in the 
amount of events and athlete participation. [1] These 
events are characterised by long distances (>26.2 miles) 
that frequently span wilderness and desert environments 
over multiple days. While many participants are treated for minor injuries 
such as blisters, sprains, tendonitis and contusions,[2] some develop more 
serious ailments like hyponatremia and rhabdomyolysis.[3-6] The extreme 
nature of these events combined with their rapidly growing participation 
base creates the potential for increased analgesic use, as compared with 
marathon and half-marathon participants, seemingly favouring non-
steroidal anti-inflammatory drug (NSAID) consumption.
In all classes of athletes, NSAIDs are one of the most commonly used 
medications for the treatment of musculoskeletal pain and inflam-
mation.[7,8] In addition to injury treatment, NSAID usage is high as a 
prophylactic treatment for anticipated pain,[9,10] as well as to enhance 
the recovery of injuries sustained during an athletic event.[11,12] While 
NSAIDs are a staple medication for the treatment of certain sports 
injuries, there is evidence to suggest that many athletes are consuming 
these medications without adequate knowledge of their intended uses 
or side-effects.[7,13] Further, there is the potential for athletes to use 
NSAIDs in dosages exceeding the recommended amount.
The most popular NSAIDs exert their effects through systemic 
cyclooxygenase (COX) inhibition, thereby reducing the amount of 
inflammation-causing prostaglandins produced by the body.[14] These 
effects are not limited to the site of injury and may be detrimental to the 
healing process of injuries involving bones and tendons. [11] They may 
also cause potentially dangerous side-effects in the gastrointestinal 
(GI) tract[15] and kidneys.[16,17] With such a wide catalogue of potential 
side-effects, it is important to examine the frequency of their use, 
particularly in ultra-endurance competitors and how they compare 
with traditional marathon runners (≤26.2 miles).
Numerous studies have focused on the incidence of NSAID use 
during endurance athlete training[5,10,12,16] and competition;[6,18] however, 
to our knowledge, no study has investigated NSAID and analgesic 
consumption at multiple timings (training, competition and rec overy) 
at a single event.
The aims of this study were: (i) to evaluate and compare the 
prevalence of NSAID and other analgesic use during the training, 
competition and recovery phases of an endurance race in two cohorts 
(ultra-endurance runners and marathon runners); and (ii) to examine 
whether participants in both cohorts used NSAIDs in accordance 
with the recommended dose or in excess thereof. 
Methods
Participants
Runners at two different endurance events, the 2011 Desert Race 
Across the Sand (RATS) and the 2011 Empire State Marathon (ESM) 
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were surveyed to evaluate their patterns of 
NSAID and analgesic use during training for 
an event, during a competition, and during 
recovery following an event. The Desert 
RATS is a 148-mile ultra-endurance run, 
performed over six days in individual stages 
of 9 - 50 miles per stage, across mountainous 
and desert terrain in Colorado and Utah, 
USA. In contrast, the ESM is a more typical 
endurance event with runners participating 
in a full-marathon, half-marathon, and 
relays of 6 - 7 miles per runner. Th e ESM 
is held in central New York State annually. 
To the authors’ knowledge, no respondent 
participated in both events.
Data collection
Data were collected via an anonymous and 
voluntary survey reviewed and deemed 
exempt by the institutional internal review 
board (239319-1). Th e survey (Table 1) was 
distributed to runners during race registration 
at both endurance events.
Statistical analysis
Using MedCalc (version 11.6.1), data were 
analysed for differences of pro portions 
between runners’ use of analgesia during 
training, competition and recovery, between 
those participating in the Desert RATS and 
ESM races.
Results
Seventy-three runners participated in the 
study: 27 ultramarathon runners from 
the Desert RATS and 46 marathon, half-
marathon and relay runners from the ESM. 
NSAIDs were the most commonly re-
ported analgesics used at both races. Fig. 1 
shows a comparison of NSAID use delineated 
by reported habits of using the recommended 
or greater-than-recommended dose. Runners 
in the ESM were more likely than those in the 
Desert RATS race (70% v. 26%, respectively) 
to use NSAIDs during a competition 
(χ2=11.76; p<0.001). Th ere were no statistical 
differences in use of NSAIDs between 
runners participating in the Desert RATS 
race when compared with those participating 
in the ESM, during training and recovery. 
In both races, acetaminophen was the next 
most commonly reported analgesic used, 
followed by topical diclofenac. Th e percentages 
of runners utilising these methods of analgesia 
for both race groups are shown in Table 2. 
Aspirin was not used by any participant who 
ran in the Desert RATS race, but was used by 
one participant who ran in the ESM. Narcotic-
based medication was reportedly used by only 
runner of each race group and only during 
their respective recoveries. 
Discussion
When comparing the prevalence of NSAID 
use between ultradistance runners and 
marathon runners, participants reported 
comparable usage during training (59% v. 
Table 1. Survey distributed to runners during event registration
1. Which of these do you use either occasionally or regularly during a race to help with 
pain and infl ammation (please select all that apply):
☐ Acetaminophen (Tylenol or other)
Do you take more than the recommended dose? Yes/No
☐ Ibuprofen (Motrin, Advil or other)
Do you take more than the recommended dose? Yes/No
☐ Narcotic-based medication (Lortab, Percocet, hydrocodone, oxycodone or other)
Do you take more than the recommended dose? Yes/No
☐ Aspirin (Bayer or other)
Do you take more than the recommended dose? Yes/No
☐ Topical Agent (Voltaren, Diclofenac or other)
Do you take more than the recommended dose? Yes/No
2. Which of these do you use either occasionally or regularly during recovery to help 
with pain and infl ammation (please select all that apply):
☐ Acetaminophen (Tylenol or other)
Do you take more than the recommended dose? Yes/No
☐ Ibuprofen (Motrin, Advil or other)
Do you take more than the recommended dose? Yes/No
☐ Narcotic-based medication (Lortab, Percocet, hydrocodone, oxycodone or other)
Do you take more than the recommended dose? Yes/No
☐ Aspirin (Bayer or other)
Do you take more than the recommended dose? Yes/No
☐ Topical agent (Voltaren, diclofenac or other)
Do you take more than the recommended dose? Yes/No
Greater than recommended dose Used as recommended
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Fig. 1. NSAID use in the Desert RATS (DR) and Empire State Marathon (ESM) runners during 
training, competition and recovery. Th e top column represents the fraction of runners that used 
NSAIDs at dosages higher than the recommended amount. *Signifi cant diﬀ erence (p<0.001).
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63%) and during recovery (59% v. 61%), but with a large discrepancy 
of usage during a race (70% v. 26%). These results do not suggest that 
more ultradistance runners use NSAIDs during training or recovery 
than traditional marathon runners. The similarity in training and 
recovery NSAID use is expected, given that both types of events 
would require relatively homogenous preparation and recuperation 
routines. Additionally, this similarity could be used as a basis for 
comparison between the two participant types, highlighting the major 
difference between the two cohorts: the elevated number of NSAID 
users in the ultradistance event. This difference could be rationalised 
by the increased duration and intensity of ultradistance events, as 
compared with marathons, increasing the probability that an athlete 
may experience pain and turn to NSAIDs.
Prophylactic use of NSAIDs is common in endurance events[5,10,12,16] 
with 59% of Ironman Brazil triathletes reporting consumption in the 
three months preceding the event,[7] a number comparable with this 
study where 59% of ultramarathon runners and 63% of marathon 
runners reported using NSAIDs during training. However, in 
addition to gastrointestinal and renal side-effects, prophylactic 
NSAID use may impede collagen synthesis and reduce tissue 
adaptation, predisposing the athlete to future injury.[16]Additionally, 
many believe that the analgesic effect of NSAIDs can mask the pain 
of an injury and thus prevent the athlete from resting enough to 
allow for proper healing.[17]
High levels of NSAID use during endurance events are fairly 
common, with self-reported usage ranging from 30% at the Ironman 
New Zealand Ultradistance Triathlon[18] to 61% at the 2002 Boston 
Marathon.[6] A study of 500 runners in two major North American 
ultramarathons showed that 60.5% of race finishers used NSAIDs 
during the race and only 28.7% of finishers did not use any medication 
at all,[1] and our survey reaffirms this difference. However, the 
significantly higher rate of NSAID consumption during a race by the 
ultradistance cohort v. the marathon cohort is concerning, and may 
put the former group at an elevated risk for adverse events.
Two major risks of NSAID use during an ultra-endurance race 
are the development of renal complications and exercise-associated 
hyponatraemia (EAH). NSAIDs reduce prostaglandin synthesis in 
the kidney, decreasing the glomerular filtration rate and afferent 
renal blood flow, which may already be lowered from exercise by 
as much as 50%.[15-17] This combination can impair the athlete’s free 
water clearance, increasing the risk for developing renal disease and/
or EAH. [1,5,7,8,17-21] The National Kidney Foundation estimates that 10% 
of kidney failure is associated with NSAID overuse.[15] While there 
are many studies that demonstrate a link between NSAID use and 
increased renal complications in athletes,[1,17-20] other studies show 
that no such correlation exists.[5] However, there is consensus that 
NSAIDs are a clear risk factor for renal disease and EAH, and it is 
recommended that these drugs are avoided by endurance athletes, 
particularly in the wilderness ultramarathon setting.[21,22]
An additional risk factor for NSAID-related adverse events is 
taking more than the recommended dose. This study did not find any 
significant difference between NSAID-using ultradistance runners 
and marathon runners with regards to surpassing the recommended 
dose in the period during training (31% v. 14%), a race (21% v. 
25%) and recovery (19% v. 25%), respectively. These results do not 
suggest that ultra-distance runners are at an increased risk from 
taking NSAIDs above the recommended dose, but only as compared 
with marathon runners. A potential future study could look to 
determine and compare the amount by which each cohort exceeds 
the recommended dose.
As attested to by its common use reported in this survey, aceta-
minophen may be a better alternative to NSAIDs for minor pain 
reduction, due to its milder effect on the GI tract, kidneys, and tissue 
regeneration.[15,20] Acetaminophen’s main adverse effects come from 
overdose-induced hepatic toxicity, and some evidence suggests that its 
pain-relieving properties may be comparable to those of NSAIDs. [14] 
Topical agents (such as diclofenac) are another group of analgesics 
used by athletes, albeit in reduced numbers (19% of ultramarathon 
runners during training in this study). The subcutaneous delivery 
to a localised site of injury makes these agents effective at treating 
minor acute musculoskeletal pain,[12,14,15,20,23] while avoiding many of 
the severe adverse reactions that NSAIDs carry.[14,20]
Encouragingly, an unpublished survey by one co-author found that 
59% of athletes surveyed would modify the frequency of their NSAID 
use if they were better educated on their potentially harmful effects. 
This represents an opportunity for medical providers involved in this 
sport’s industry to improve the health and safety of endurance race 
participants. One particular opportunity for education, at least popular 
in ultramarathon events, is the pre-race medical briefing, where 
medical directors and race staff have the ability to provide evidence-
based guidelines to runners before the event commences. 
Conclusion
Despite the well-documented, undesirable side-effects associated 
with NSAID use, there was a high incidence of use in our cohort of 
runners, particularly during a race in the ultramarathon group. More 
effort should be made to inform runners about the potential hazards 
of NSAID misuse and to offer alternatives to oral NSAIDs for minor 
pain relief. If necessary, NSAID use should be limited to a short-term 
regimen, taken after the injury, and for the intended purposes only.
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Table 2. Acetaminophen and diclo fenac use during the Desert 
RATS and ESM races 
Desert RATS ESM
During training
Acetaminophen
Topical diclofenac
26%
19%
15%
4%
During competition
Acetaminophen
Topical diclofenac
11%
7%
11%
2%
During recovery
Acetaminophen
Topical diclofenac
11%
4%
17%
4%
Desert RATS = Desert Race Across the Stand; ESM = Empire State Marathon.
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